Blueprint Medicines to Present at Upcoming Investor Conferences
Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company, announced its participation in two upcoming investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company, announced its participation in two upcoming investor conferences. The Stifel 2022 Healthcare Conference will take place in New York, NY on November 16, 2022 at 2:25 p.m. ET. Additionally, the JMP Securities Hematology and Oncology Summit will be held virtually on December 7, 2022 at 10:20 a.m. ET. Webcasts of the presentations will be available on the company's website for 30 days after each event.
Details
News Market Reaction – BPMC
The recorded move for BPMC in the trading session of this news was +5.87%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 9, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (Nasdaq: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced its participation the following upcoming investor conferences:
- Stifel 2022 Healthcare Conference in New York, NY on Wednesday, November 16, 2022 at 2:25 p.m. ET.
- JMP Securities Hematology and Oncology Summit, held virtually, on Wednesday, December 7, 2022 at 10:20 a.m. ET.
A live webcast of each presentation will be available by visiting the "Events and Presentations" section of Blueprint Medicines' website at http://ir.blueprintmedicines.com. A replay of the webcasts will be archived on Blueprint Medicines' website for 30 days following each presentation.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders. Today, we are delivering our approved medicines to patients in the United States, Europe, and in other geographies ourselves or through our partners. In addition, we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer, and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-present-at-upcoming-investor-conferences-301673455.html
SOURCE Blueprint Medicines Corporation
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.